ALX Oncology Holdings Inc
Veridion Score
Composite trend over time
Why is ALXO moving today?
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ALXO.
ALXO insider activity
ALX Oncology Holdings Inc
No multi-insider buying cluster in the last 90 days
Net buying: $5.1M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-23 | 2026-03-19 | Pinto Shelly | Insider | sell | $2.17 | 903 | 86,805 | $2K | SEC Form 4 |
| 2026-03-23 | 2026-03-19 | Lettmann Jason | Insider | sell | $2.17 | 12,311 | 293,609 | $27K | SEC Form 4 |
| 2026-02-20 | 2026-02-18 | Pinto Shelly | Insider | sell | $2.27 | 565 | 87,708 | $1K | SEC Form 4 |
| 2026-02-19 | 2026-02-17 | Lettmann Jason | Insider | sell | $2.27 | 2,201 | 305,920 | $5K | SEC Form 4 |
| 2026-02-04 | 2026-02-02 | GOODMAN COREY S | Insider | buy | $1.57 | 3,184,713 | 8,453,038 | $5.0M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 7 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moALXO contract awards, year to date.
Public federal awards linked to this ticker.
ALXO lobbying filings, year to date.
Registered lobbying filings matched to ALX Oncology Holdings Inc.